Free Trial

VolitionRx Q1 2023 Earnings Report

VolitionRx logo
$0.55 +0.02 (+4.17%)
As of 03/28/2025 04:00 PM Eastern

VolitionRx EPS Results

Actual EPS
-$0.15
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

VolitionRx Revenue Results

Actual Revenue
$0.15 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

VolitionRx Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

VolitionRx Earnings Headlines

3VNRX : A Look Ahead: VolitionRX's Earnings Forecast
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More VolitionRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like VolitionRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VolitionRx and other key companies, straight to your email.

About VolitionRx

VolitionRx (NYSE:VNRX), a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

View VolitionRx Profile

More Earnings Resources from MarketBeat